GlassScriptPhysician profile
Pamela A Lui
NPI 1457315525
$1,229.94
in general payments reported to CMS, 2019-2025
18 companies · $136 in 2025
The $136 reported for 2025 was less than what a typical Obstetrics & Gynecology provider received nationally (typical 2025 total: $158).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $94.81 · 2020: $17.19 · 2021: $217 · 2022: $295 · 2023: $187 · 2024: $281 · 2025: $136.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $605.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $605.13 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $504.50 | 2021-2024 | |
| Coopersurgical, INC. | $121.92 | 2019-2024 | Paragard T 380a, Paragard T 380a |
| Bayer Healthcare Pharmaceuticals INC. | $114.83 | 2019-2025 | |
| Gynesonics, INC. | $80.12 | 2023-2024 | Sonata Sonography-Guided Transcervical Fibroid Ablation System |
| Hologic Sales and Service, LLC | $73.21 | 2024-2025 | Myosure Tissue Removal Device, Aptima, Acessa Provu System |
| Exeltis, USA INC. | $57.91 | 2021-2025 | Slynd |
| Biogen, INC. | $46.59 | 2025 | Zurzuvae |
| Millicent US INC | $40.29 | 2024-2025 | Femlyv, Femring, Intrarosa |
| Avion Pharmaceuticals | $31.39 | 2021-2023 | Balcoltra |
| Astellas Pharma US INC | $25.98 | 2024 | Veozah |
| Pfizer INC. | $25.72 | 2024 | |
| Merck Sharp & Dohme LLC | $24.26 | 2021 | |
| Medtronic, INC. | $22.66 | 2023 | Truclear |
| Mayne Pharma Commercial LLC | $17.35 | 2022 | |
| Organon LLC | $15.22 | 2022 |
Show all 17 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Lupin INC. | $14.98 | 2019 | |
| Minerva Surgical, INC | $13.01 | 2023 |
1 company reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
Research and ownership
$2.00 in ownership or investment interests, as reported to CMS. These are holdings a clinician or an immediate family member has in a company, not payments received.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Pamela Lui listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.